News Brief
Summary
Stock prices for Eli Lilly and Novo Nordisk fell after former President Donald Trump announced a goal to reduce the price of brand-name GLP-1 weight loss drugs to $150 per month. A government official clarified that no formal price agreements have been made with the drugmakers yet. Shares of Hims & Hers Health also dropped sharply.
Key Points
- Stock Decline: Eli Lilly shares fell 2%, Novo Nordisk shares fell 3%, and Hims & Hers Health shares plunged over 15%.
- Price Target: Trump stated an aim to lower the cash price of drugs like Ozempic to $150, a significant reduction from current U.S. list prices.
- Official Clarification: Dr. Mehmet Oz emphasized that price negotiations for GLP-1 drugs have not yet been finalized.
- Market Impact: A $150 price would undercut even current compounded GLP-1 alternatives, potentially reshaping the cash pay market.
- Broader Context: The administration has been pressuring pharmaceutical companies to align U.S. drug prices with those in other developed countries.
新闻简报
总结
在前总统唐纳德·特朗普宣布计划将品牌GLP-1减肥药的价格降至每月150美元后，礼来公司和诺和诺德公司的股价下跌。一位政府官员澄清，尚未与制药公司达成正式价格协议。Hims & Hers Health的股价也大幅下挫。
关键点
- 股价下跌：礼来公司股价下跌2%，诺和诺德股价下跌3%，Hims & Hers Health股价暴跌超过15%。
- 价格目标：特朗普声称目标是像Ozempic这类药物的现金支付价格降至150美元，较当前美国标价大幅降低。
- 官方澄清：Mehmet Oz博士强调，GLP-1药物的价格谈判尚未最终敲定。
- 市场影响：150美元的价格将比目前复合GLP-1药物的替代品更便宜，可能重塑现金支付市场。
- 背景信息：政府一直在向制药公司施压，要求将美国药品价格与其他发达国家看齐。
Original Article Link: https://www.cnbc.com/2025/10/17/eli-lilly-novo-nordisk-stock-trump-glp-1-prices.html